Search

Your search keyword '"Schetelig, Johannes"' showing total 1,367 results

Search Constraints

Start Over You searched for: Author "Schetelig, Johannes" Remove constraint Author: "Schetelig, Johannes"
1,367 results on '"Schetelig, Johannes"'

Search Results

2. How risky is a second allogeneic stem cell transplantation?

3. Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

4. Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence

5. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT

6. Chronic Lymphocytic Leukemia

7. Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial

8. Correction: Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT

9. Outcomes of haploidentical transplants with PT-CY vs 10/10 MUD transplants with ATG in Germany

10. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)

12. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

13. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

14. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial

15. Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002

18. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

19. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia

20. Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy

22. Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML

23. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome

24. Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

25. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

26. Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation

27. Following Transplantation for Acute Myelogenous Leukemia, Donor KIR Cen B02 Better Protects against Relapse than KIR Cen B01.

29. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia

33. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial

36. Macroscopic, histologic, and clinical assessment of acute graft-versus-host disease of the upper gastrointestinal tract within 6 weeks after allogeneic hematopoietic cell transplantation

38. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study

39. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

41. Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears

42. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

43. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

44. Supplementary Tables 1 from Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study

45. Data from Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study

46. Supplementary Figure 1 from Improvements in Posttransplant Outcomes Over Two Decades in Older Patients with Acute Myeloid Leukemia in the EBMT ALWP Study

47. Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight

49. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

Catalog

Books, media, physical & digital resources